New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics
14 Mai 2018 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology, announced new scientific advisors in
immuno-oncology and autoimmunity. The advisors hail from
prestigious international institutions and collectively have both
scientific and clinical expertise in cell therapies in these areas.
“The advisors we’ve assembled include researchers and physicians
who are luminaries in their fields,” said Intellia President and
Chief Executive Officer John Leonard, M.D. “Pursuing both in vivo
and ex vivo pipelines, Intellia has a broad spectrum approach to
genome editing in a variety of therapeutic applications using our
CRISPR/Cas9 technology. We look forward to working alongside these
experts and benefiting from their deep experience and insight, to
drive development of our wholly owned ex vivo programs in
immuno-oncology and autoimmunity.”
The following scientific leaders and clinicians are Intellia’s
advisors on ex vivo cell therapy in immuno-oncology:
- Evren Alici, M.D., Ph.D., assistant professor and group leader,
hematology, Karolinska Institutet, Sweden
- Chiara Bonini, M.D., Ph.D., full professor, Università
Vita-Salute San Raffaele; deputy director, Division of Immunology,
Transplantation and Infectious Diseases, Ospedale San Raffaele; and
head, Experimental Hematology Unit, Ospedale San Raffaele,
Italy
- Daniel DeAngelo, M.D., Ph.D., associate professor of medicine,
Harvard Medical School, and director, clinical and translational
research, adult leukemia, Dana Farber Cancer Institute, United
States
- Saar Gill, M.D., Ph.D., assistant professor of medicine, Center
for Cellular Immunotherapies, University of Pennsylvania, United
States
- Johanna Olweus, M.D., Ph.D., full professor and head,
Department of Cancer Immunology, University of Oslo, and director,
K.G. Jebsen Center for Cancer Immunotherapy, Norway
- E. John Wherry, Ph.D., Richard and Barbara Schiffrin
President's Distinguished Professor of Microbiology, and
director, Institute for Immunology, University of
Pennsylvania, United States
- Juan Carlos Zúñiga-Pflücker, Ph.D., professor and chair,
Department of Immunology, University of Toronto, and senior
scientist, Sunnybrook Research Institute, Canada
These experts are Intellia’s advisors on ex vivo cell therapy in
autoimmunity:
- Laurence Turka, M.D., chief scientific officer, Rheos
Medicines; deputy director, Immune Tolerance Network; and
professor of surgery and medicine (part-time), Massachusetts
General Hospital and Harvard Medical School, United
States
- Kathryn Wood, D.Phil., F.Med.Sci., emeritus professor of
immunology, Nuffield Department of Surgical Sciences, University of
Oxford, United Kingdom
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through optimized cell therapies that can treat cancer
and immunological diseases by replacing patients’ diseased cells.
The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Intellia within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, express or implied statements regarding our
ability to advance and expand the CRISPR/Cas9 technology to develop
into human therapeutic products, as well as our CRISPR/Cas9
intellectual property portfolio; our ability to achieve stable or
effective genome editing; the potential development of ex vivo cell
therapeutics of all types, including immuno-oncology and
autoimmunity therapies, using CRISPR/Cas9 technology; and the
impact of our collaborations and relationships with our partners
and scientific advisors on our development programs. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs of future events, and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: risks related to
Intellia’s ability to protect and maintain our intellectual
property position; risks related to the ability of our licensors to
protect and maintain their intellectual property position;
uncertainties related to the initiation and conduct of studies and
other development requirements for our product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies will not be predictive of future
results in connection with future studies; and the risk that
Intellia’s collaborations with IRCCS Ospedale San Raffaele,
Novartis or Regeneron, or Intellia’s other ex vivo or in vivo
collaborations, will not continue or will not be successful. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K and quarterly reports on
Form 10-Q filed with the Securities and Exchange Commission, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and Intellia Therapeutics undertakes
no duty to update this information unless required by law.
Intellia
Contacts: |
|
|
Media: |
|
|
Jennifer Mound
Smoter |
|
Lynnea Olivarez |
Senior Vice
President |
|
Associate Director |
External Affairs &
Communications |
|
External Affairs &
Communications |
+1 857-706-1071 |
|
+1 956-330-1917 |
jenn.smoter@intelliatx.com |
|
lynnea.olivarez@intelliatx.com |
|
|
|
Investors: |
|
|
Lindsey Trickett |
|
|
Vice President |
|
|
Investor Relations |
|
|
+1 857-285-6211 |
|
|
lindsey.trickett@intelliatx.com |
|
|
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024